Filing Flows › Immucell (ICCC) › Q4 2025
Immucell (ICCC) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 30, 2026
Immucell (ICCC) reported revenue of $7.6M for the fourth quarter 2025 (Q4 2025), -2% from a year earlier and +39% from the quarter before. Operating margin was -0.8%, net loss $2.8M (37.4% of revenue).
Immucell, Q4 2025: revenue $7.6M (-2% year over year), operating margin -0.8%, net loss $2.8M, operating cash flow $483K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.6M | +39% | -2% |
| Operating profit | −$58K | -389% | -109% |
| Net earnings | −$2.8M | — | -654% |
| Operating cash flow | $483K | — | — |
| Free cash flow | $310K | — | — |
What changed
Revenue was $7.6M in Q4 2025, down 2% year over year and up 39% from the previous quarter.
Gross margin was 38.2%, up 1.6 points from Q4 2024. Operating costs exceeded revenue by $58K, an operating margin of -0.8%. Operating expenses grew 34% against a revenue fall of 2%. The fastest-growing cost line was General & admin (+103%). The quarter ended with a net loss of $2.8M, wider than the previous quarter's $140K loss. Net interest and other expense of $2.8M was the main reason.
Operating cash flow was $483K. Non-cash charges added back $709K of depreciation and amortization and $104K of share-based compensation. Working capital and other items added $2.5M. Capital expenditures of $172K left free cash flow of $310K.
Questions
What was Immucell's revenue in the fourth quarter 2025?
Immucell (ICCC) reported revenue of $7.6M for the fourth quarter 2025 (Q4 2025), -2% from a year earlier and +39% from the quarter before.
Was Immucell profitable in the fourth quarter 2025?
Operating loss was $58K (-0.8% of revenue) and net loss $2.8M.
Source: Immucell 10-K on SEC EDGAR.